Skip to main content

Prenatal cell-free DNA (cfDNA) screening of chromosome abnormalities: A technical standard of the American College of Medical Genetics and Genomics (ACMG) and the College of American Pathologists (CAP)

In brief

ACMG and CAP set laboratory standards for prenatal DNA screening

A new technical standard offers laboratories guidance on validating prenatal cell-free DNA tests, monitoring performance, and interpreting and reporting results. The groups cite this screening as the most sensitive and specific option for common fetal chromosome abnormalities, and professional societies recommend offering it to all pregnant people regardless of risk; the standard aims to make laboratory practices more consistent.

Journal
Genetics in medicine : official journal of the American College of Medical Genetics (Q1)
Published
13 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1c)
Authors
Benjamin A Hilton, Sucheta Bhatt, Phillip Cacheris, Sung-Hae L Kang, Edward M Kloza, Brynn Levy, et al.
PMID
43033073
DOI
10.1016/j.gim.2026.102743

Why clinicians should know about it

  • Picked for Genetics (clinical) (paper of the day, 16 November 2026): ACMG/CAP technical standard guides prenatal cfDNA practice

Abstract

The American College of Medical Genetics and Genomics and the College of American Pathologists work group developed this technical standard to address challenges associated with laboratory validation and implementation of prenatal cell-free DNA (cfDNA) screening. Given that cfDNA screening is the most sensitive and specific screening test available for common fetal aneuploidies, the American College of Medical Genetics and Genomics, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine recommend that prenatal cfDNA screening be offered to all pregnant persons as a first-tier screening option, regardless of their risk status. Fetal cfDNA in maternal circulation originates from placenta-derived trophoblasts, allowing for the identification of fetuses at increased risk for trisomies 13, 18, and 21 and aneuploidy of sex chromosomes, in addition to recurrent segmental aneuploidies associated with syndromes. Multiple cfDNA analysis techniques exist, and because of the complex nature of this screening, this technical standard aims to promote uniform laboratory practices. This document deals with the technical standards applicable to prenatal cfDNA screening of chromosome abnormalities in maternal plasma. This document serves as a resource to assist clinical laboratories with the validation methods, ongoing monitoring of test quality and performance, and the interpretation and reporting of these results.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.